LONDON, October 10, 2018 /PRNewswire/ --
THIS ANNOUNCEMENT CONTAINS INSIDE
INFORMATION WITHIN THE MEANING OF THE EU MARKET ABUSE REGULATION
NO.596/2014
Arix Bioscience plc (LSE: ARIX) ("Arix"), a global healthcare
and life science company supporting medical innovation, today notes
that LogicBio Therapeutics Inc.("LogicBio") has filed an amended
registration statement on Form S-1 with the U.S. Securities and
Exchange Commission (the "SEC") relating to a proposed initial
public offering in the United
States of shares of its common stock.
The registration statement discloses an indicative pricing range
for the proposed offering of U.S.$12.00- U.S.$14.00
per common share. This would represent an increase in value of
Arix's current shareholding in LogicBio (compared to the £4.9
million sterling holding value) of £15.9 - £19.4
million[1]. The proposed maximum aggregate offering
amount specified in the filing is U.S.$75.0
million, which assumes that the offering price is at the
midpoint of the indicative pricing range and does not include the
underwriters' option to purchase additional common shares.
Arix has indicated an interest in purchasing common shares in
the offering, subject to agreement with the underwriters.
The registration statement can be accessed through the SEC's
EDGAR database. The registration statement relating to the shares
of common stock has been filed with the SEC but has not yet become
effective. The shares may not be sold nor may offers to buy be
accepted prior to the time the registration statement becomes
effective.
This announcement does not constitute an offer to sell or the
solicitation of an offer to buy securities, and shall not
constitute an offer, solicitation or sale in any jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of that
jurisdiction.
The securities referred to in this release are to be offered
only by means of a prospectus. When available, copies of the
preliminary prospectus can be obtained from Jefferies LLC,
Attention: Equity Syndicate Prospectus Department, 520 Madison
Avenue, 2nd Floor, New York, NY
10022, or by telephone at (877) 821-7388, or by email at
Prospectus_Department@Jefferies.com.
About Arix Bioscience plc
Arix Bioscience plc is a global healthcare and life science
company supporting medical innovation. Headquartered in
London and with an office in
New York, Arix Bioscience sources,
finances and builds world class healthcare and life science
businesses addressing medical innovation at all stages of
development. Operations are supported by privileged access to
breakthrough academic science and strategic relationships with
leading research accelerators and global pharmaceutical
companies.
Arix Bioscience plc is listed on the Main Market of the London
Stock Exchange.
About LogicBio
LogicBio Therapeutics is a genome editing company focused on
developing medicines to durably treat rare diseases in patients
with significant unmet medical needs using GeneRide™, its
proprietary technology platform. GeneRide™ enables the
site-specific integration of a therapeutic transgene, in a
nuclease-free and promotorless approach by relying on the native
process of homologous recombination to drive lifelong expression.
Headquartered in Cambridge,
Massachusetts, LogicBio is committed to developing medicines
that will transform the lives of pediatric patients and their
families.
References:
1. At exchange rate on 9 October
2018
Enquiries
For more information on Arix, please contact:
Arix Bioscience plc
Charlotte
Parry, Head of Investor Relations
+44(0)20-7290-1072
charlotte@arixbioscience.com
Optimum Strategic Communications
Mary Clark, Supriya Mathur
+44(0)203-714-1787
optimum.arix@optimumcomms.com
Burns McClellan (US Media & IR Enquiries)
Nancie Steinberg, Bill Slattery Jr.
+1-212-213-0006
arix@burnsmc.com